RxDoctor Payments Data

Timothy Morgan, PA

Physician Assistant · Anchorage, AKNPI 1578540159

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $591, 2.5 times the $235 reported in 2023.

$1,082in general payments, 2019–2025

Across 55 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Antares Pharma, Inc.$241
  • Edwards Lifesciences$160
  • AbbVie$147
  • Novo Nordisk$91
  • Gilead$63
  • AstraZeneca$54
  • plus $327 from 12 others

What the payments were for

  • Food & beverage$1,082100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,082 in reported general payments places this provider in the 80th percentile of 365 physician assistant providers in Alaska.

See all physician assistant providers in Alaska

Medicare billing

Part B allowed, 2024
$35,684
Medicare patients
96
Services billed
273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide13$12,112
SynthroidLevothyroxine Sodium12$836
Gabapentin14$244
Metoprolol Succinate11$227
Lisinopril32$213
Pantoprazole Sodium19$184
Atorvastatin Calcium24$160
Levothyroxine Sodium22$148
Simvastatin13$80
Amlodipine Besylate22$73
Meloxicam13$18

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$91$12,11213 claims
AbbVieSynthroid$147$83612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 365 physician assistant providers in Alaska.

Other physician assistant in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →